p.s. One has to wonder if XOM will try to fold in IMO at some point instead of maintaining the awkward “arms-length” status XOM has with IMO when it comes to XOM’s dealmaking in Canada. The relationship reminds me of Roche and Genentech before Roche finally bought out the minority shareholders.
The politics would be messy, of course. Comments?
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.